WP
MBX

Woodline Partners’s MBX Biosciences MBX Stock Holding History

Woodline Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.9M Sell
900,063
-100,000
-10% -$3.4M 0.1% 271
2025
Q4 		$31.5M Sell
1,000,063
-201,087
-17% -$4.88M 0.12% 215
2025
Q3 		$21M Buy
1,201,150
+300,047
+33% +$4.01M 0.1% 272
2025
Q2 		$10.3M Buy
901,103
+23,642
+3% +$241K 0.05% 429
2025
Q1 		$6.48M Buy
877,461
+268,740
+44% +$2.84M 0.04% 442
2024
Q4 		$11.2M Buy
608,721
+89,046
+17% +$1.9M 0.08% 315
2024
Q3 		$13.5M Buy
+519,675
New +$11.9M 0.11% 245

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Woodline Partners's MBX Position: Q1 2026 in Review

Woodline Partners reduced its MBX Biosciences (MBX) stake by 10% in Q1 2026, selling an estimated $3.4M and leaving 900,063 shares worth $26.9M. The position accounts for 0.1% of the portfolio, ranked #271.

Woodline Partners first reported a position in MBX in Q3 2024 and has held it in 7 quarters since. The position peaked at $31.5M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Woodline Partners held 900,063 shares of MBX Biosciences worth $26.9M as of Q1 2026.
  • Woodline Partners sold 100,000 MBX Biosciences shares in Q1 2026, an estimated $3.4M.
  • MBX Biosciences made up 0.1% of Woodline Partners's portfolio in Q1 2026, its #271 holding.
  • Woodline Partners first reported a position in MBX Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Woodline Partners's MBX Biosciences position peaked at $31.5M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.